Search Results - technology+classifications+%3e+research+tools+%3e+peptides

4 Results

Sort By:

Chemokine-derived Peptides that Induce Immunogenic Cancer Cell Death

Value PropositionHigh cancer cell specificity by cell surface characteristics.High water solubility.Combination of oncolytic and anti-angiogenic properties.Unmet NeedThere currently are no peptides reported to have both oncolytic and anti-angiogenic activities. Additionally, drug development requires solubility in water; however, the reported oncolytic...

Published: 9/27/2024 | Inventor(s): Aleksander Popel, Natsuki Furukawa, Niranjan Pandey, Adam Mirando

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Peptides, Technology Classifications > Therapeutic Modalities > Peptides

Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same

Value Proposition:· Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads· Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity· Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...

Published: 9/27/2024 | Inventor(s): Hai-Quan Mao, Stephany Tzeng, Jordan Green, Yizong Hu, Sashank Reddy, Leonardo Cheng

Keywords(s):

KRAS Inhibitor

KRAS Oncogene InhibitorJHU Ref #: C16567Value Proposition· KRAS oncogene function inhibitor· 24 amino acid peptide synthesized from KRAS4B structure· Enables development of KRAS-driven cancer therapeuticsUnmet NeedKRAS is an oncoprotein involved in cell division regulation with gene mutations leading to cellular transformations...

Published: 9/27/2024 | Inventor(s): Miho Iijima, Hiroshi Senoo, Hiromi Sesaki

Keywords(s):

Category(s): Technology Classifications > Research Tools > Peptides, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology

Cyclic Peptide Inhibitors of USP22

Unmet Need:According to the CDC, each year approximately 1.6-million individuals will be diagnosed with cancer and an estimated 600,000 people will succumb to the disease in the United States alone (see CDC). Treatment of cancer is based on tissue type as well as the stage in which the cancer is diagnosed. Most therapies include cytotoxic agents with...

Published: 9/27/2024 | Inventor(s): Cynthia Wolberger, Michael Morgan, Hiroaki Suga

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Peptides